Clinical Trial - Trial HKUCTR-2993
Access comprehensive clinical trial information for HKUCTR-2993 through Pure Global AI's free database. This Phase 2 trial is sponsored by ENYO Pharma SA and is currently Recruitment Completed. The study focuses on Infection.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to HKU CLINICAL TRIALS REGISTRY data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
HKUCTR-2993
Phase 2
Recruitment Completed
drug
Trial Details
HKU CLINICAL TRIALS REGISTRY • HKUCTR-2993
Untitled Trial
A Phase 2a open-label study of the oral Farnesoid X Receptor (FXR) modulator EYP001a to assess its safety and anti-viral effect in chronic Hepatitis B (CHB) patients in combination with pegylated interferon alpha2a (peg-IFN) alone and with entecavir (ETV)
Study Focus
Sponsor & Location
ENYO Pharma SA
China
Timeline & Enrollment
Phase 2
N/A
Sep 05, 2021
ICD-10 Classifications
Bacterial infection, unspecified
Bacterial, viral and other infectious agents
Infection following immunization
Other infectious diseases
Viral infection, unspecified
Data Source
HKU CLINICAL TRIALS REGISTRY
HKUCTR-2993
Non-Device Trial